Wednesday, November 30, 2016 8:55:06 AM
PURE Bioscience Sets Fiscal 2017 Q1 Results Conference Call
Food Safety Solutions Update on PURE® Hard Surface and PURE Control® Antimicrobials
November 30, 2016 08:36 AM Eastern Standard Time
SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that on December 14, 2016 the Company will file its Form 10-Q shortly after the close of the market. It will host an investor conference call that day at 1:30pm PST (4:30pm EST) to review 2017 Q1 financial results.
PURE management will also discuss the progress made to commercialize its two antimicrobial SDC-based food safety solutions:
PURE® Hard Surface disinfectant - The status of ongoing commercialization in restaurant chains (including Chipotle Mexican Grill) and processors/manufacturers.
PURE Control® - The status of ongoing sales and marketing of FDA approved processing aid for fresh produce; the status of the work for USDA approval for use as a raw poultry processing aid;
The Participant Dial-In Number for the conference call is 1-631-891-4304. Participants should dial in to the call at least five minutes before 1:30pm PST (4:30pm EST) on December 14, 2016. The call can also be accessed “live” online at http://public.viavid.com/index.php?id=122082.
A replay of the recorded call will be available for 90 days on the Company’s website (http://www.purebio.com/investors/events-presentations/). You can also listen to a replay of the call by dialing 1-844-512-2921 (international participants dial 1-412-317-6671) starting December 14, 2016, at 7:30pm EST through December 21, 2016 at 11:59 pm EST. Please use PIN Number 10002105.
Recent PURE News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:30:15 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/10/2024 09:30:10 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/19/2023 09:45:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/14/2023 09:10:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 09:05:40 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/30/2023 08:10:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2023 08:23:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2023 08:20:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2023 08:19:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2023 08:17:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2023 08:15:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2023 08:14:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2023 08:13:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2023 08:30:36 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM